Is Vaccine Latecomer Inovio Making a Comeback?
Inovio Pharmacauticals (NASDAQ: INO) once was among the most prominent companies in the coronavirus vaccine race. The biotech designed its vaccine candidate in only three hours after receiving the coronavirus genetic sequence. And it started a phase 1 trial only a few weeks after one of today's market leaders, Moderna.
Since then, a series of events has pushed Inovio to the back of the pack. The most damaging was the U.S. government's decision to drop funding of its late-stage clinical trial. That was due to the supply of vaccines already on the market. But recently, Inovio announced news that could jump-start its vaccine program. Let's look at the details and find out what this means for the stock.
Image source: Getty Images.
Source Fool.com
